Kezar Life Sciences Inc (KZR)
0.7633
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
0.7633
0.00 (0.00%)
After-Hours: 20:00
Kezar Life Sciences SG&A Expense (Quarterly): 6.539M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.539M |
| December 31, 2023 | 5.76M |
| September 30, 2023 | 8.789M |
| June 30, 2023 | 5.785M |
| March 31, 2023 | 6.206M |
| December 31, 2022 | 5.175M |
| September 30, 2022 | 5.067M |
| June 30, 2022 | 4.977M |
| March 31, 2022 | 4.934M |
| December 31, 2021 | 4.322M |
| September 30, 2021 | 3.972M |
| June 30, 2021 | 3.668M |
| March 31, 2021 | 3.762M |
| December 31, 2020 | 2.951M |
| September 30, 2020 | 3.292M |
| Date | Value |
|---|---|
| June 30, 2020 | 2.705M |
| March 31, 2020 | 3.021M |
| December 31, 2019 | 2.566M |
| September 30, 2019 | 2.601M |
| June 30, 2019 | 2.43M |
| March 31, 2019 | 2.382M |
| December 31, 2018 | 1.753M |
| September 30, 2018 | 1.60M |
| June 30, 2018 | 1.722M |
| March 31, 2018 | 1.514M |
| December 31, 2017 | 0.783M |
| September 30, 2017 | 0.635M |
| June 30, 2017 | 0.436M |
| March 31, 2017 | 0.426M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.43M
Minimum
Jun 2019
8.789M
Maximum
Sep 2023
4.426M
Average
4.147M
Median
SG&A Expense (Quarterly) Benchmarks
| Accuray Inc | 22.73M |
| Tonix Pharmaceuticals Holding Corp | 9.31M |
| Acumen Pharmaceuticals Inc | 5.325M |
| NovaBay Pharmaceuticals Inc | 3.346M |
| Palatin Technologies Inc | 2.033M |